LANADELUMAB EFFICACY AFTER SWITCHING FROM PLACEBO: RESULTS FROM THE HELP AND HELP OPEN-LABEL EXTENSION STUDIES

被引：1
|
作者：
Tachdjian, R.
Anderson, J.
Busse, P.
Johnston, D.
Kiani, S.
Nurse, C.
Paes, K.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2018年 / 121卷 / 05期
关键词：
D O I：
10.1016/j.anai.2018.09.119
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P171
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [1] LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Riedl, M.
    Cicardi, M.
    Hao, J.
    Lu, P.
    Li, H.
    Manning, M.
    Bernstein, J.
    Busse, P.
    Tachdjian, R.
    Gower, R.
    Wedner, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S31
  • [2] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Banerji, A.
    Hao, J.
    Yu, M.
    Bernstein, J.
    Johnston, D.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
  • [3] Efficacy of Lanadelumab in Hereditary Angioedema Patients Switching From C1 Inhibitor Long-Term Prophylaxis: Interim Results From the HELP Open-Label Extension Study
    Riedl, Marc A.
    Anderson, John T.
    Cicardi, Marco
    Li, H. Henry
    Lockey, Richard F.
    Longhurst, Hilary
    Maurer, Marcus
    Lu, Peng
    Hao, James
    Banerji, Aleena
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB38 - AB38
  • [4] LANADELUMAB REDUCES HAE ATTACK RATE: INTERIM FINDINGS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Riedl, M.
    Bernstein, J.
    Yang, W.
    Longhurst, H.
    Magerl, M.
    Hebert, J.
    Shennak, M.
    Martinez-Saguer, I.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S37 - S37
  • [5] Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study
    Paes, Kim
    Bernstein, Jonathan
    Longhurst, Hilary
    Aygoren-Pursun, Emel
    Ren, Hong
    Craig, Timothy
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB145 - AB145
  • [6] Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Long-Term Prophylaxis Use: Interim Results From the HELP Open-Label Extension Study
    Paes, Kim
    Craig, Timothy
    Bernstein, Jonathan
    Longhurst, Hilary
    Aygoren-Pursun, Emel
    Nurse, Christina
    Zuraw, Bruce
    Jacobs, Joshua
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB102 - AB102
  • [7] Lanadelumab is well-tolerated and effective across patient subgroups: Findings from the HELP open-label extension study
    Maurer, M.
    Lumry, W. R.
    Li, H. H.
    Jacobs, J.
    Soteres, D.
    Lu, P.
    Hao, J.
    Banerji, A.
    ALLERGY, 2020, 75 : 60 - 60
  • [8] Lanadelumab efficacy and safety after switching from androgens: analysis of the phase 3 HELP and HELP OLE studies for hereditary angioedema
    Lumry, William
    Johnston, Douglas
    Riedl, Marc
    Choudhry, Zia
    Nurse, Christina
    Yegin, Ashley
    Juethner, Salome
    Banerji, Aleena
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB166 - AB166
  • [9] Long-term prevention of attacks with lanadelumab across subgroups of patients with hereditary angioedema (HAE): final results from the HELP open-label extension study
    Maurer, M.
    Bernstein, J. A.
    Jacobs, J.
    Lumry, W. R.
    Ren, H.
    Soteres, D.
    Yu, M.
    Martinez-Saguer, I
    ALLERGY, 2021, 76 : 10 - 10
  • [10] An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
    Riedl, Marc A.
    Bernstein, Jonathan A.
    Craig, Timothy
    Banerji, Aleena
    Magerl, Markus
    Cicardi, Marco
    Longhurst, Hilary J.
    Shennak, Mustafa M.
    Yang, William H.
    Schranz, Jennifer
    Baptista, Jovanna
    Busse, Paula J.
    CLINICAL AND TRANSLATIONAL ALLERGY, 2017, 7
12345